Logo

The US FDA Accepts Amgen's BLA for Tarlatamab and Granted Priority Review for Advanced Small Cell Lung Cancer

Share this
Amgen

The US FDA Accepts Amgen's BLA for Tarlatamab and Granted Priority Review for Advanced Small Cell Lung Cancer

Shots:

  • The BLA was submitted based on the results from the P-II (DeLLphi-301) clinical trial evaluating tarlatamab (10mg & 100mg, Q2W) patients (N=220) with advanced SCLC in 2 cohorts with median follow up of either 10.6mos. (10mg) or 10.3mos. (100mg). The assigned PDUFA date for tarlatamab is Jun 12, 2024
  • The results from the trial showed among patients evaluable for antitumor activity & survival (n=68), OR occurred in 40% (10mg) & 32% (100mg), DoR of 6mos. in 59%, mPFS of 4.9mos. & 3.9mos. whereas OS at 9mos. was depicted in 68% & 66% of the patients4
  • Tarlatamab is an investigational DLL3 targeting BiTE therapy developed by Amgen as a targeted therapy for SCLC. Earlier in Oct 2023, the US FDA also granted a BTD to tarlatamab

Ref: Amgen | Image: Amgen

Related News:- Q32 Bio Signs an Agreement with Amgen to Retrieve the Rights to Bempikibart (ADX-914) for Autoimmune Diseases

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Kritika Jha

Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions